SCHEMBL6921904

SCHEMBL6921904

CNCC(O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 0.61
CYP2D6 P10635 10/20 0.61
TDP1 Q9NUW8 3/20 0.61
KDM4E B2RXH2 3/20 0.61
ADRB2 P07550 3/20 0.61
HIF1A Q16665 3/20 0.61
ADRB1 P08588 3/20 0.61
ADRA2A P08913 3/20 0.61
ADRB3 P13945 3/20 0.61
ADRA2B P18089 3/20 0.61
ADRA2C P18825 3/20 0.61
MEN1 O00255 2/20 0.61
MAPT P10636 2/20 0.61
KMT2A Q03164 2/20 0.61
ALDH1A1 P00352 2/20 0.61
TSHR P16473 2/20 0.61
DRD1 P21728 2/20 0.61
ADRA1A P35348 2/20 0.61
ADRA1B P35368 2/20 0.61
DRD3 P35462 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8565017 0.98 KDM4E (0.62) CYP3A4CYP2D6TDP1KDM4EADRB2
SCHEMBL6052738 0.86 KDM4E (0.72) CYP3A4CYP2D6TDP1KDM4EADRB2
Dichloroisoproterenol SCHEMBL613952 0.82 ADRB2 (0.63) CYP3A4CYP2D6TDP1KDM4EADRB2
Dichloroisoproterenol SCHEMBL29139831 0.82 ADRB2 (0.63) CYP3A4CYP2D6TDP1KDM4EADRB2
SCHEMBL24303162 0.82 SLC6A4 (0.51) CYP3A4CYP2D6ALDH1A1SLC6A3SLC6A2
SCHEMBL13971033 0.81 SLC6A2 (0.50) CYP3A4CYP2D6SLC6A3SLC6A2SLC6A4
SCHEMBL758732 0.81 SLC6A2 (0.49) CYP3A4CYP2D6ALDH1A1SLC6A3SLC6A2
SCHEMBL28320405 0.81 ADRB2 (0.67) CYP3A4CYP2D6TDP1KDM4EADRB2
Hydrochloric Acid SCHEMBL9317350 0.80 SLC6A2 (0.67) CYP3A4CYP2D6SLC6A3SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL8923703 0.80 LMNA (0.68) CYP3A4CYP2D6TDP1KDM4EADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515023-B2 For inhibiting the aggregation of blood platelets; 3-(4-Aminomethyl-phenyl)-1-(2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl)-1 -isopropyl-urea for example MERCK & CO., INC. 2003-02-04 US disclosed
US-20020007045-A1 Thrombin receptor antagonists MERCK & CO., INC. 2002-01-17 US disclosed
EP-0700386-A1 NEUROKININ RECEPTOR ANTAGONISTS SANOFI (FR) 1996-03-13 EP disclosed
WO-1995026338-A1 NEUROKININ RECEPTOR ANTAGONISTS SANOFI (FR) 1995-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007045-A1 Thrombin receptor antagonists F2R, TBXA2R, PTAFR CYP3A4 727/4885CYP2D6 1576/4885TDP1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.